PRODUCT INFORMATION
METOPROLOL SANDOZ® 50MG and 100MG TABLETS

NAME OF THE MEDICINE

Chemical name: di[(RS)-3-{4-(2-methoxyethyl)phenoxy]-1-(isopropylamino)propan-2-ol] tartrate
Generic name: Metoprolol tartrate
Chemical Structure:

CAS Number: 56392-17-7 (C_{15}H_{28}NO_{3})_2 \cdot C_4H_6O_6 MW = 684.8

DESCRIPTION

Metoprolol tartrate is a white crystalline powder. Melting point: approximately 120°C. The powder is practically odourless. It is very soluble in water, soluble in chloroform, methylene chloride and alcohol, and almost insoluble in benzene, diethyl ether and acetone.

In addition to metoprolol tartrate, Metoprolol Sandoz® tablets also contain lactose, maize starch, microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica, hydroxypropylcellulose, calcium hydrogen phosphate and crospovidone.

PHARMACOLOGY

Pharmacodynamics
Metoprolol tartrate is structurally related to other cardioselective β-blockers. It is a relatively cardioselective β-adrenoceptor blocking medicine without intrinsic sympathomimetic activity, and is suited for the treatment of hypertension. It acts on β1-receptors mainly located in the heart at lower doses than those needed to influence the β2-receptors mainly located in the bronchi and peripheral vessels. Metoprolol reduces blood pressure in patients with hypertension, in both the standing and supine position. It also reduces the extent of rises in blood pressure occurring in response to physical and mental stress. In angina pectoris metoprolol reduces the frequency and severity of the attacks and the need for glyceryl trinitrate relief, and increases exercise tolerance.

Metoprolol has been shown to reduce mortality in patients with suspected or definite myocardial infarction. The mechanisms of action for these effects are not fully understood but may be related to a lower incidence of ventricular fibrillation and limitation of infarct size. Metoprolol has also been shown to reduce the incidence of recurrent myocardial infarction.
In cases of supraventricular tachycardia or atrial fibrillation, and in the presence of extra systoles, metoprolol has a regulating effect on the heart rate.

Orthostatic effects or disturbances of electrolyte balance have not been observed.

In therapeutic doses, metoprolol has less effect on the peripheral circulation and the bronchial muscles than non-selective β-blockers. However, metoprolol should be used with caution in patients with asthma, and concomitant use of an adrenergic bronchodilator, e.g. terbutaline or salbutamol, is advisable. Patients with reversible airways obstruction who are already taking β2-stimulants may require adjustment of the dosage of these if metoprolol therapy is subsequently introduced.

The stimulant effect of catecholamines on the heart is reduced or inhibited by metoprolol. This leads to a decrease in heart rate, cardiac contractility, and cardiac output. Metoprolol will inhibit catecholamine induced lipolysis. It has also been shown to reduce diuretic induced increases in plasma renin activity. Metoprolol will inhibit catecholamine induced insulin secretion to a far lesser degree than non-selective β-blockers.

Metoprolol is practically devoid of membrane stabilising activity and does not display partial agonist activity (i.e. intrinsic sympathomimetic activity = ISA) at doses required to produce β-blockade.

Metoprolol tartrate forms an active metabolite which does not, however, contribute significantly to the therapeutic effect.

Metoprolol is considered a relatively lipid soluble compound, i.e. less soluble than propranolol and more lipid soluble than atenolol. It has been shown to exert a prophylactic effect in both classical and common migraine.

Pharmacokinetics
Metoprolol is rapidly and almost completely (more than 95%) absorbed from the gastrointestinal tract. It is rapidly and extensively distributed to the extravascular tissues. The volume of distribution is 5.6L/kg. At therapeutic concentrations, approximately 12% is bound to human serum proteins. Studies with the radioactively labelled drug have shown that more than 90% of the dose is excreted in the urine within 72 hours, mainly in the form of known metabolites. Only about 3% of the administered dose is excreted unchanged in the urine in 72 hours. The rate of renal excretion of metoprolol has a linear relationship to its plasma concentration. Metoprolol is excreted mainly by glomerular filtration.

Long-term studies have shown that metoprolol neither enhances nor inhibits its own metabolism.

The elimination half-life of metoprolol tartrate is between three and five hours. The duration of the β-blocking effect is dose dependent (as measured by reduction of exercise heart rate).

INDICATIONS
Hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

CONTRAINDICATIONS
- Bronchospasm. β-Adrenergic blockade of the smooth muscle of bronchioles may result in an increased airways resistance. These medicines also reduce the effectiveness of asthma treatment. This may be dangerous in susceptible patients.
Therefore, β-blockers are contraindicated in any patient with a history of airways obstruction or a tendency to bronchospasm. Use of cardioselective β-blockers can also result in severe bronchospasm. If such therapy must be used, great caution should be exercised. Alternative therapy should be considered.

- Allergic disorders (including allergic rhinitis) which may suggest a predisposition to bronchospasm.
- Right ventricular failure secondary to pulmonary hypertension.
- Significant right ventricular hypertrophy.
- Sinus bradycardia (less than 45 to 50 beats/minute).
- Second and third degree atrioventricular block.
- Shock (including cardiogenic and hypovolaemic shock).
- Hypersensitivity to metoprolol tartrate.
- Hypersensitivity to any of the excipients in Metoprolol Sandoz®.
- Sensitivity to other β-blockers as cross sensitivity between β-blockers can occur.
- Non-compensated congestive heart failure (see Precautions).
- Sick-sinus syndrome.
- Severe peripheral arterial circulatory disorders.
- Myocardial infarction patients with a heart rate of < 45 beats/minute, a PR interval of > 0.24 seconds, a systolic blood pressure of < 100mmHg and/or moderate to severe non-compensated heart failure.
- Hypotension.
- Untreated phaeochromocytoma (see Precautions).
- Continuous or intermittent inotropic therapy acting through β-receptor agonism.

**PRECAUTIONS**

Use with caution in the following circumstances:

**Bronchospastic disease.** In general, patients with bronchospastic disease should not be given beta-blockers of any type (e.g. selective or nonselective), including metoprolol. If such therapy must be used, great caution should be exercised. Alternative therapy should be considered. However, because of its relative cardioselectivity, oral metoprolol may be administered with caution to patients with mild or moderate bronchospastic diseases who do not respond to, or cannot tolerate, other suitable treatments. Since β₁-selectivity is not absolute, a β₂-agonist should be administered concomitantly, and the lowest possible dose of metoprolol should be used.

**Cardiac failure.** β-blockade depresses myocardial contractility and may precipitate cardiac failure in some patients with a history of cardiac failure, chronic myocardial insufficiency, or unsuspected cardiomyopathy. In patients without a history of cardiac failure, continuing depression of the myocardium may lead to cardiac failure. If signs of cardiac failure are present, the patient should be fully digitalised and/or given a diuretic and carefully monitored. If cardiac failure develops metoprolol should be discontinued gradually (see Abrupt withdrawal, Precautions below). β-blockers should not be used in patients with uncontrolled congestive heart failure; this condition should first be stabilised.

Because of their negative effect on atrioventricular conduction, beta-blockers, including metoprolol, should be given only with caution with first degree atrioventricular block (see Contraindications).

Note. Although congestive heart failure has been considered to be a contraindication to the use of β-blockers, there is growing literature on the experimental use of β-adrenergic blocking medicines in heart failure. As further trials are needed to identify which patients are most likely to respond to which medicines, β-blockers including metoprolol should not normally be prescribed for heart failure outside specialist centres.
**Myocardial infarction.** In patients with myocardial infarction, if significant hypotension occurs, metoprolol should be discontinued, and the hemodynamic status of the patient and the extent of myocardial ischemia carefully assessed. Intensive hemodynamic monitoring may be required and appropriate treatment modalities should be instituted. If hypotension is associated with significant bradycardia or atrioventricular block, treatment should be directed at reversing these.

**Abrupt withdrawal.** Care should be taken if β-blockers have to be discontinued abruptly in patients with coronary artery disease. Severe exacerbation of angina and precipitation of myocardial infarction and ventricular arrhythmias have occurred following abrupt discontinuation of β-blockade in patients with ischaemic heart disease. Therefore it is recommended that the dosage be reduced gradually over a period of 8 to 14 days during which time the patient’s progress should be assessed. Metoprolol should be temporarily reinstituted if the angina worsens. If the medicine must be withdrawn abruptly in these patients, close observation is required. In the perioperative period, metoprolol should not be withdrawn unless withdrawal is specifically indicated.

**Effects on the heart rate.** If the patient develops increasing bradycardia (heart rate less than 50 to 55 beats/minute) the dosage of metoprolol should be gradually reduced or treatment gradually withdrawn (see Contraindications).

**Peripheral circulation.** β-Blockade may impair the peripheral circulation and exacerbate the symptoms of peripheral vascular disease (see Contraindications). Metoprolol should be used with caution in patients with peripheral arterial circulatory disorders (for example, Raynaud’s disease or phenomenon, intermittent claudication).

**Prinzmetal angina.** There is a risk of exacerbating the number and duration of coronary artery spasms if patients with Prinzmetal angina or variant angina pectoris are treated with a β-blocker including metoprolol. If this treatment is essential, it should only be undertaken in a coronary or intensive care unit.

**Diabetes.** Metoprolol should be used with caution in patients with diabetes mellitus, especially those who are receiving insulin or oral hypoglycaemic agents. Diabetes patients should be warned that β-Blockers including metoprolol affect glucose metabolism and may mask some important premonitory signs of acute hypoglycaemia, such as tachycardia. In patients with insulin or non-insulin dependent diabetes, especially labile diabetes, or with a history of spontaneous hypoglycaemia, β-blockade may result in the loss of diabetic control and delayed recovery from hypoglycaemia. The dose of insulin or oral hypoglycaemic agent may need to be adjusted. Diabetic patients receiving metoprolol should be monitored to ensure that diabetes control is maintained.

**Other metabolic effects.** β-Adrenoreceptors are involved in the regulation of lipid as well as carbohydrate metabolism. Some medicines affect the lipid profile adversely although the long-term clinical significance of this change is unknown and the effect appears to be less for medicines with intrinsic sympathomimetic activity.

**Phaeochromocytoma.** In patients with this condition, or suspected of having this condition an α-blocking medicine (e.g. phentolamine or phenoxybenzamine) should be administered before the β-blocker to avoid exacerbation of hypertension.

**Eye and skin reactions.** Various rashes and conjunctival xerosis have been reported with β-blocking agents. Cross reactions may occur between β-blockers, therefore substitutions within the group may not necessarily preclude occurrence of symptoms.

During long-term treatment with the β-blocking medicine practolol a specific rash bearing a superficial resemblance to psoriasis was occasionally described. In a number of patients affected, this rash was accompanied by adverse effects on the eye (xerophthalmia and/or keratoconjunctivitis) of varying severity. This condition is called the oculomucocutaneous or practolol syndrome. On a few rare
occasions, serious otitis media, sclerosing peritonitis and pleurisy have been reported as part of this syndrome.

The oculomucocutaneous syndrome reported with practolol has not been reported with metoprolol. However, dry eyes and skin rash have been reported with metoprolol. If such symptoms occur, discontinuation of metoprolol should be considered.

More recently, an association between Peyronie’s disease (a fibrosing induration of the penis) and various β-blockers has been suggested but is not proven.

**Allergic conditions.** Allergic reactions may be exaggerated by β-blockade (e.g. allergic rhinitis during the pollen season and allergic reactions to bee and wasp stings). β-blockers including metoprolol should be avoided if there is a risk of bronchospasm.

In patients taking β-blockers including metoprolol, anaphylactic shock assumes a more severe form and may be resistant to normal doses of adrenaline. Whenever possible, β-blockers including metoprolol should be avoided in patients who are at increased risk of anaphylaxis.

**Hyperthyroidism.** Special care should be exercised in those patients who are hyperthyroid and also receiving beta-blockers because β-blockers may mask the clinical signs of developing or continuing hyperthyroidism, resulting in symptomatic improvement without any change in thyroid status, special care should be exercised in hyperthyroid patients who are also receiving β-blockers. Where metoprolol is administered to patients having, or suspected of developing thyrotoxicosis, both thyroid and cardiac function should be monitored closely.

**Interactions.** Calcium channel blocker of the verapamil (phenylalkylamine) type should not be given intravenously to patients receiving metoprolol because there is a risk of cardiac arrest in this situation (see “Interactions with Other Medicines”).

**Euthyroid hyperthyroxinaemia.** The effects of β-blockers on thyroid hormone metabolism may result in elevations of serum free thyroxine (T₄) levels. In the absence of any signs or symptoms of hyperthyroidism, additional investigation is necessary before a diagnosis of thyrotoxicosis can be made.

**Impaired renal function.** In patients with severe renal disease, haemodynamic changes following β-blockade may impair renal function further. β-blockers, which are excreted mainly by the kidney, may require dose adjustment in patients with renal failure.

**Conduction disorders.** Very rarely, a pre-existing A-V conduction disorder of moderate degree may become aggravated (possibly leading to A-V block). Metoprolol should be administered with caution to patients with first degree A-V block (see **Contraindications**).

**Hepatic impairment.** Metoprolol is mainly eliminated by means of hepatic metabolism (see **Pharmacokinetics**). Therefore, hepatic impairment may increase the systemic bioavailability of metoprolol and reduce its total clearance, leading to increased plasma concentrations.

**Use in the Elderly.** Caution is indicated in elderly patients. An excessive decrease in blood pressure or pulse rate may cause the blood supply to vital organs to fall to inadequate levels.

**Women of child-bearing potential.** Upon confirming the diagnosis of pregnancy, women should immediately inform the doctor.

**Use in pregnancy (Category C)**
In general, no drug should be taken during the first 3 months of pregnancy, and the relative benefits and risks of treatment should be carefully considered throughout pregnancy.
β-blockers may cause pharmacological effects such as bradycardia in the foetus and newborn infant.

Experience with metoprolol in the first trimester of pregnancy is limited, but no foetal malformations attributable to metoprolol have been reported. However, beta-blockers may reduce placental perfusion, and clinical experience suggests that in cases where its use is considered to be essential, metoprolol may be administered during pregnancy.

During the later stages of pregnancy these medicines should only be given after weighing the needs of the mother against the risk to the foetus.

The lowest possible dose should be used and treatment should be discontinued at least 2 to 3 days before delivery to avoid increased uterine contractility and effects of β-blockade in the newborn (e.g. bradycardia, hypoglycaemia).

Animal studies have not demonstrated adverse maternal or foetal effects except in high doses in the rabbit, where slight reduction of litter size and slightly higher value of foetal loss were demonstrated.

There are few clinical data on the use of metoprolol tartrate during the first trimester of pregnancy.

Metoprolol crosses the placental barrier in pregnant women; in one study the concentration in the umbilical vein was almost the same as in maternal vein plasma.

**Use in lactation**
Metoprolol is excreted in human breast milk. β-blockers taken by the mother may cause side effects, e.g. bradycardia, in the breastfed infant, although when the doses used are within the recommended therapeutic range, the very small amount of the drug ingested by the infant renders such effects unlikely. Experience suggests that metoprolol only need be discontinued during lactation if the infant’s hepatic function is severely impaired.

**Paediatric use**
The safety and efficacy of metoprolol in children have not been established.

**Effects on ability to drive or use machinery**
Metoprolol may cause dizziness, fatigue or visual disturbances (see *Adverse Effects*) and, therefore, may adversely affect the patient’s ability to drive or use machinery.

**INTERACTIONS WITH OTHER MEDICINES**

**Effects of other medicinal products on metoprolol**
The effects of metoprolol and other antihypertensive drugs on blood pressure are usually additive. Patients receiving concurrent treatment with catecholamine depleting drugs, other beta-blockers (including those in form of eye drops), or monoamine oxidase (MAO) inhibitors, should be carefully monitored.

**Concomitant therapy with calcium antagonists.** The concomitant use of calcium antagonists with myocardial suppressant and sinus node activity (e.g. verapamil and to a lesser extent diltiazem) and β-blockers may cause bradycardia, hypotension and asystole. Extreme caution is required if these medicines have to be used together. A calcium channel blocker of the phenylalkylamine type (i.e. verapamil) should not be administered intravenously to patients receiving metoprolol because there is a risk of cardiac arrest in this situation. Concomitant administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility due to negative chronotropic and inotropic effects. Patients taking an oral calcium blocker of this type in combination with metoprolol should be closely monitored. The combination of β-blockers with dihydropyridine calcium channel blockers with a weak myocardial effect (e.g. felodipine, nifedipine)
can be administered together with caution. In case excess hypotension develops, the calcium antagonist should be stopped or the dosage reduced.

When metoprolol is given together with calcium antagonists of the verapamil and diltiazem type the patient should be monitored for possible negative inotropic and chronotropic effects. Calcium antagonists of the verapamil type should not be given by intravenous administration to patients treated with β-blockers.

**CYP2D6 Inhibitors.** Potent inhibitors of this enzyme may increase the plasma concentration of metoprolol. Strong inhibition of CYP2D6 would result in the change of phenotype into poor metaboliser. Caution should therefore be exercised when coadministering potent CYP2D6 inhibitors with metoprolol. Known clinically significant potent inhibitors of CYP2D6 are antidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, desipramine, antipsychotics such as chlorpromazine, fluphenazine, haloperidol, thiouridazine, antiarrhythmics such as quinidine or propafenone, antiretrovirals such as ritonavir, antihistamines such as diphenhydramine, antimalarials such as hydroxychloroquine or quinidine, antifungals such as terbinafine and medications for stomach ulcers such as cimetidine.

**Hydralazine.** Concomitant administration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol.

**Antiarrhythmic medicines.** Care should be taken when prescribing β-blockers with antiarrhythmic medicines. Interactions have been reported during concomitant β-blocker therapy with the class IA agents disopyramide, procainamide, ajmaline and less frequently quinidine; class IB agents, tocainide, mexiletine and lignocaine; class IC agents, flecainide and propafenone (not available in Australia); the class III agent, amiodarone; and the class IV antiarrhythmic agents (e.g. verapamil). Particularly, in patients with pre-existing sinus node dysfunction, concomitant administration of amiodarone may result in additive electro-physiologic effects including bradycardia, sinus arrest, and atrioventricular block.

When metoprolol is given together with antiarrhythmic agents the patient should be monitored for possible negative inotropic and chronotropic effects. The negative inotropic and negative chronotropic effects of antiarrhythmic agents of the quinidine type and amiodarone may be enhanced by β-blockers.

**Anaesthesia and the perioperative period.** The necessity or desirability of withdrawing beta-blocking agents prior to major surgery is controversial. The impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anaesthesia and surgical procedures. The benefits of continuing a treatment with a beta-blocker should be balanced against the risk of withdrawing it in each patient.

β-Blockade may have beneficial effects in decreasing the incidence of arrhythmias and myocardial ischaemia during anaesthesia and the postoperative period. It is currently recommended that maintenance β-blockade be continued perioperatively. The anaesthetist must be made aware of β-blockade because of the potential for interactions with other medicines, resulting in severe bradyarrhythmias and hypotension, the decreased reflex ability to compensate for blood loss, hypovolaemia and regional sympathetic blockade, and the increased propensity for vagal induced bradycardia. Incidents of protracted severe hypotension or difficulty restoring normal cardiac rhythm during anaesthesia have been reported.

Acute initiation of high-dose metoprolol to patients undergoing non-cardiac surgery should be avoided, since it has been associated with bradycardia, hypotension and stroke including fatal outcome in patients with cardiovascular risk factors.

Modern inhalational anaesthetic agents are generally well tolerated, although older agents (ether, cyclopropane, methoxyflurane, trichlorethylene) were sometimes associated with severe circulatory depression in the presence of β-blockade. If it is thought necessary to withdraw β-blocker therapy
before surgery, this should be done gradually and be completed about 48 hours before surgery (see Abrupt withdrawal, Precautions).

**Glyceryl Trinitrate:** Glyceryl Trinitrate may enhance the hypotensive effect of metoprolol.

**Hepatic enzyme inhibitors:** Enzyme –inhibiting substances may exert an influence on the plasma concentration of metoprolol. The plasma concentration of metoprolol may be raised by cimetidine.

**Non-steroidal anti-inflammatory drugs.** Concomitant administration of non-steroidal anti-inflammatory drugs including COX-2 inhibitors with a beta-blocker such as indomethacin may decrease the antihypertensive effect of metoprolol.

**Effect of metoprolol on other medicines**

**Use of catecholamine depleting agents.** Concomitant use of medicines such as reserpine and guanethidine requires careful monitoring since the added effect of a β-blocker may produce an excessive reduction of the resting sympathetic nervous tone.

**Anti-adrenergic agents.** Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by beta-blockers. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. Concurrent use of β-blockers and clonidine should be avoided because of the risk of adverse interaction and severe symptoms. If administered concomitantly, the clonidine should not be discontinued until several days after the withdrawal of the β-blocker. The rebound hypertension associated with clonidine withdrawal can be exacerbated by the presence of a beta-blocker. If both drugs are withdrawn simultaneously, a marked rise in blood pressure and/or arrhythmias may result.

**Other anti-hypertensive agents.** Metoprolol enhances the effects of other antihypertensive medicines. Particular care is required when initiating administration of a β-blocker and prazosin together.

**Sympathetic ganglion blocking agents, other β-blockers or monoamine oxidase (MAO) inhibitors.** Patients receiving concomitant treatment with sympathetic ganglion blocking agents, other β-blockers (including eye drops), or monoamine oxidase (MAO) inhibitors should be kept under close surveillance.

**Prostaglandin synthetase inhibiting agents.** Concomitant treatment with indomethacin or other prostaglandin synthetase inhibiting agents may decrease the antihypertensive effect of β-blockers.

**Alcohol.** Metoprolol may modify the pharmacokinetic behaviour of alcohol when taken together. The plasma level of metoprolol may be raised by alcohol.

**Liver enzyme effects.** Enzyme-inducing and enzyme-inhibiting substances may change the plasma level of metoprolol. The plasma level of metoprolol is lowered by rifampicin and may be raised by cimetidine, alcohol, hydralazine and selective serotonin re-uptake inhibitors (SSRIs), e.g. paroxetine, fluoxetine and sertraline.

**Antidiabetic drugs and insulin.** Beta-blockers may interfere with the usual hemodynamic response to hypoglycemia and produce a rise in blood pressure associated with severe bradycardia. Beta-blockers may also antagonise the hypoglycaemic effects of sulfonylureas. The risk of either effect is less with a beta1-selective drug such as metoprolol than with a non-selective beta-blocker. However, diabetic patients receiving metoprolol should be monitored to ensure that diabetes control is maintained (see Precautions).
**Anaesthetics.** Inhalation anaesthetics enhance the cardiosuppressant effect of beta-blocker therapy (see **Precautions**). Metoprolol may also reduce the clearance of other drugs (e.g. lignocaine).

**Warfarin.** A limited number of reports have demonstrated a rise in AUC and concentration of warfarin when taken with another β-blocker. This could potentially increase the anti-coagulant effect of warfarin.

**Digitalis glycosides.** Digitalis glycosides, in association with beta blockers, may increase atrioventricular conduction time and may induce bradycardia. Monitoring heart rate and PR interval is recommended.

**Ergot alkaloid.** Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids.

**Dipyridamole.** In general, administration of a beta-blocker should be withheld before dipyridamole testing, with careful monitoring of heart rate following the dipyridamole injection.

**ADVERSE EFFECTS**

Cardiovascular adverse effects (related, possibly related, unassessable or unknown) reported by ≥1% in 1,395 patients during randomised clinical trials of metoprolol and placebo:

<table>
<thead>
<tr>
<th>Adverse Effect</th>
<th>Metoprolol (%)</th>
<th>Placebo (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotension (systolic BP &lt; 90 mmHg)</td>
<td>27.4%</td>
<td>23.2%</td>
</tr>
<tr>
<td>Bradycardia (heart rate &lt; 40 beats/min)</td>
<td>15.9%</td>
<td>6.7%</td>
</tr>
<tr>
<td>Second- or third-degree heart block</td>
<td>4.7%</td>
<td>4.7%</td>
</tr>
<tr>
<td>First-degree heart block (P-R &gt; 0.26 sec)</td>
<td>5.3%</td>
<td>1.9%</td>
</tr>
<tr>
<td>Heart failure</td>
<td>27.5%</td>
<td>29.6%</td>
</tr>
</tbody>
</table>

**Tabulated summary of adverse drug reactions from clinical trials**

Adverse drug reactions from clinical trials are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

**Adverse drug reactions from clinical trials**

**Blood and the lymphatic system disorders**
- Rare agranulocytosis
- Very rare thrombocytopenia

**Psychiatric disorders**
- Rare depression, nightmares
- Very rare personality disorder, hallucinations, mental confusion
Nervous system disorders
Common  dizziness, headache
Rare     depressed level of consciousness, somnolence or insomnia, paraesthesia
         Short term memory loss

Eye disorders
Very rare visual impairment (e.g. blurred vision), dry eyes eye irritation

Ear and labyrinth disorders
Very rare tinnitus, hearing disorders\(^1\) (e.g. hypoacusis or deafness)

Cardiac disorders
Common  bradycardia
Rare     cardiac failure, arrhythmias, palpitation
Very rare conduction disorders, precordial pain

Vascular disorders
Common  orthostatic hypotension (occasionally with syncope), peripheral oedema, hypertension
         (mild and transient), cold extremities, arterial insufficiency
Rare     oedema, Raynaud's phenomenon
Very rare Gangrene\(^2\)
         angina (mild and transient), intermittent claudication

Respiratory, thoracic and mediastinal disorders
Common  dyspnea, exertional dyspnoea
Rare     Bronchospasm\(^3\)
Very rare rhinitis

Gastrointestinal disorders
Common  nausea and vomiting, abdominal pain, heartburn, flatulence, gastric pain
Rare     diarrhoea or constipation
Very rare dry mouth, retroperitoneal fibrosis (relationship to metoprolol has not been definitely established)
         unstable diabetes

Hepatobiliary disorders
Very rare Hepatitis

Skin and subcutaneous tissue disorders
Common  pruritis, rash
Rare     rash (in the form of urticaria, psoriasiform and dystrophic skin lesions)
Very rare Photosensitivity reaction, hyperhydrosis, reversible alopecia, worsening of psoriasis
         sweating increased
**Musculoskeletal, connective tissue disorders**
- Rare: muscle spasms
- Very rare: arthritis, musculoskeletal pain

**Reproductive system and breast disorders**
- Very rare: erectile dysfunction, libido disorder and potency, Peyronie’s disease

**Immune system disorders**
- hypersensitivity

**General disorders and administration site conditions**
- Common: fatigue, tiredness

**Investigations**
- Very rare: weight gain, liver function test abnormal

1. in doses exceeding those recommended
2. in patients with pre-existing severe peripheral circulatory disorders
3. which may occur in patients without a history of obstructive lung disease
4. relationship to metoprolol has not been definitely established

Discontinuation of the drug should be considered if any such reaction is not otherwise explicable.

The oculomucocutaneous syndrome associated with the beta-blocker, practolol, has not been reported with metoprolol (see “PRECAUTIONS”).

**Post-marketing Data**
In addition to the adverse events reported in the clinical trials, the following events have been reported during post-marketing surveillance of metoprolol*:

**Nervous system disorders:**
- confusional state

**Investigations:**
- increase in blood triglycerides, decrease in high density lipoprotein (HDL)

*Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.*

**Potential Adverse Reactions**
A variety of adverse reactions not listed above have been reported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to metoprolol.

**Cardiac disorders**
- intensification of AV block (see “CONTRAINDICATIONS”)

**Blood and the lymphatic system disorders**
- nonthrombocytopenic purpura, thrombocytopenic purpura
Nervous system disorders

reversible mental depression progressing to catatonia, an acute
reversible syndrome characterised by disorientation for time and
place, short-term memory loss, emotional lability, slightly clouded
sensorium, and decreased performance in neuropsychometrics

Hypersensitivity reactions

fever combined with aching and sore throat, laryngospasm, and
respiratory distress

DOSAGE AND ADMINISTRATION

Metoprolol Sandoz® is recommended for oral therapy in hypertension, angina pectoris, suspected or
definite myocardial infarction and migraine prophylaxis.

Hypertension

Initially. Mild hypertension: 50 or 100mg once daily for one week.
Severe hypertension: 50 or 100mg twice daily for one week.
Maintenance. 50 or 100mg once or twice daily.

Some patients will respond to 50mg once daily. However, a large number of patients will respond to
100mg once daily as initial and maintenance therapy. Response is rarely improved by increasing the
dose beyond 200mg daily. The maximum daily dose should not exceed 400mg. Although twice daily
dosage is optimal in patients where maintenance dosage is 150mg daily or less, it may be administered
as a single dose.

Angina Pectoris

50 to 100mg two or three times daily.

Myocardial infarction

Initially. Therapy should commence with Metoprolol Sandoz® 50mg tablets twice daily and be
continued for 48 hours.
Maintenance. The oral maintenance dose is generally 100mg twice daily.

Migraine prophylaxis

100 to 150mg given in divided doses morning and evening.

OVERDOSAGE

Contact the Poison Information Centre on 13 11 26 for advice on management of overdose.

Symptoms: Overdosage is characterised by excessive bradycardia, hypotension, possible cardiac
failure and bronchoconstriction. AV block, cardiogenic shock, impairment of consciousness (even
coma), convulsions, nausea, vomiting and cyanosis may also occur. Concomitant ingestion of alcohol,
antihypertensives, quinidine or barbiturates may aggravate the patient's condition. The first signs of
overdose can appear in 20 minutes after ingestion of tablets, but are more commonly seen within one
to two hours. The effects of massive overdosage may persist for several days despite declining plasma
concentrations.

Treatment: Metoprolol Sandoz® should be withdrawn. The patient should be hospitalised and,generally, should be managed in an intensive care setting with continuous monitoring of cardiac
function, blood gases, and blood biochemistry. Emergency supportive measures such as artificial
ventilation or cardiac pacing should be instituted if appropriate. Even apparently well patients who
have taken a small overdose should be closely observed for signs of poisoning for at least 4 hours.
In general, patients with acute or recent myocardial infarction may be more haemodynamically unstable than other patients and should be treated accordingly.

In the event of a potentially life-threatening oral overdose, use induction of vomiting or gastric lavage (if within 4 hours after ingestion of metoprolol) and/or activation charcoal to remove the drug from the gastrointestinal tract. Haemodialysis is unlikely to make a useful contribution to metoprolol elimination.

Atropine may be given intravenously to control significant bradycardia. Intravenous beta-agonists such as prenalterol or isoprenaline should be used to treat bradycardia and hypotension; very high doses may be needed to overcome the beta-blockade. Dopamine, dobutamine or noradrenaline may be given to maintain blood pressure. Glucagon has positive inotropic and chronotropic effects on the heart that are independent of beta-adrenergic receptors, and has proved effective in the treatment of resistant hypotension and heart failure associated with beta-blocker overdose.

Diazepam is the drug of choice for controlling seizures. A beta-agonist or aminophylline can be used to reverse bronchospasm; patients should be monitored for evidence of cardiac arrhythmias during and after administration of the bronchodilator.

The beta-blocker withdrawal phenomenon (see Precautions) may occur after overdose.

**PRESENTATION AND STORAGE CONDITIONS**

Metoprolol Sandoz® 50mg Tablets: White, round, biconvex, with a score notch on one side.
PVC/PVDC Aluminium blister packs of 100 tablets

Metoprolol Sandoz® 100mg Tablets: White, round, biconvex, with a score notch on one side.
PVC/PVDC Aluminium blister packs of 60 tablets

Store below 25°C.
Protect from light and moisture.

**NAME AND ADDRESS OF THE SPONSOR**

Sandoz Pty Ltd
ABN 60 075 449 553
54 Waterloo Road
Macquarie Park, NSW 2113
Australia
Tel: 1800 634 500

**POISON SCHEDULE OF THE MEDICINE**

Schedule 4 – Prescription Only Medicine

**Date of first inclusion in the Australian Register of Therapeutic Goods (the ARTG):**
17/12/1997

**Date of most recent amendment:** 21/01/2016